Abstract
Inhibition of the NLRP3 inflammasome is a promising strategy for the development of new treatments for inflammatory diseases. MCC950 is a potent and specific small-molecule inhibitor of the NLRP3 pathway, but its molecular target is not defined. Here, we show that MCC950 directly interacts with the Walker B motif within the NLRP3 NACHT domain, thereby blocking ATP hydrolysis and inhibiting NLRP3 activation and inflammasome formation.
Similar content being viewed by others
Data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
References
Boucher, D. et al. J. Exp. Med. 215, 827–840 (2018).
Broz, P. & Dixit, V. M. Nat. Rev. Immunol. 16, 407–420 (2016).
Prochnicki, T., Mangan, M. S. & Latz, E. F1000Res. 5, 1469 (2016).
Guo, H., Callaway, J. B. & Ting, J. P. Nat. Med. 21, 677–687 (2015).
Broderick, L. et al. Annu. Rev. Pathol. 10, 395–424 (2015).
De Nardo, D., De Nardo, C. M. & Latz, E. Am. J. Pathol. 184, 42–54 (2014).
Coll, R. C. et al. Nat. Med. 21, 248–255 (2015).
van Hout, G. P. et al. Eur. Heart. J. 38, 828–836 (2017).
Primiano, M. J. et al. J. Immunol. 197, 2421–2433 (2016).
Kim, R. Y. et al. Am. J. Respir. Crit. Care Med. 196, 283–297 (2017).
Tate, M. D. et al. Sci. Rep. 6, 27912 (2016).
Kammoun, H. L. et al. Mol. Metab. 10, 66–73 (2018).
Moffat, J. G. et al. Nat. Rev. Drug Discov. 16, 531–543 (2017).
Gross, C. J. et al. Immunity 45, 761–773 (2016).
Gaidt, M. M. et al. Immunity 44, 833–846 (2016).
Shi, H. et al. Nat. Immunol. 17, 250–258 (2016).
White, C. S., Lawrence, C. B., Brough, D. & Rivers-Auty, J. Brain Pathol. 27, 223–234 (2017).
Van Gorp, H. et al. Proc. Natl Acad. Sci. USA 113, 14384–14389 (2016).
Lomenick, B. et al. Proc. Natl Acad. Sci. USA 106, 21984–21989 (2009).
Schroder, K. & Tschopp, J. Cell 140, 821–832 (2010).
Duncan, J. A. et al. Proc. Natl Acad. Sci. USA 104, 8041–8046 (2007).
Hu, Z. et al. Science 341, 172–175 (2013).
Tenthorey, J. L. et al. Science 358, 888–893 (2017).
Wendler, P., Ciniawsky, S., Kock, M. & Kube, S. Biochim. Biophys. Acta 1823, 2–14 (2012).
Tapia-Abellán, A. et al. Nat. Chem. Biol. https://doi.org/10.1038/s41589-019-0278-6 (2019).
Mariathasan, S. et al. Nature 430, 213–218 (2004).
Schroder, K. et al. Proc. Natl Acad. Sci. USA 109, E944–E953 (2012).
Lomenick, B., Jung, G., Wohlschlegel, J. A. & Huang, J. Curr. Protoc. Chem. Biol. 3, 163–180 (2011).
Pai, M. Y. et al. Methods Mol. Biol. 1263, 287–298 (2015).
Xu, C. P. et al. Chem. Biol. 16, 980–989 (2009).
Mackinnon, A. L. & Taunton, J. Curr. Protoc. Chem. Biol. 1, 55–73 (2009).
Stols, L. et al. Protein Expr. Purif. 25, 8–15 (2002).
Acknowledgements
This work was supported by the National Health and Medical Research Council of Australia (Fellowship 1138466 and Program Grant no. 1071659 to M.P.J.; Fellowship no. 1141131 to K.S.; Project Grant no. 1086786 to A.A.B.R. and K.S.), the Australian Research Council (Fellowship no. FT130100361 to K.S.), the Institute for Molecular Bioscience (Research Advancement Award to J.H.) and The University of Queensland (Postdoctoral Fellowships to R.C.C. and D.B.; Research Scholarship to J.H.). We thank D. Edwards for chemical purification and analytical support, M. Cooper (University of Queensland) for providing MCC950 and K. Stacey (University of Queensland) for providing ASC-deficient mice.
Author information
Authors and Affiliations
Contributions
R.C.C. designed and performed most experiments. J.R.H. conceived and synthesized the photoaffinity probe and performed labeling experiments. C.J.D. and M.P.J. designed and performed SPR analysis. A.Z. designed and cloned the NLRP3 expression plasmids and mutants. D.B. expressed and purified recombinant NLRP3 and assisted with experimental design. N.L.M synthesized the photoaffinity probe. J.L.C. and J.A.F. assisted with the expression and purification of recombinant NEK7, A.A.B.R. formulated MCC950, conceived the photoaffinity probe and expressed and purified recombinant NEK7. A.A.B.R. and K.S. designed experiments and supervised the study. R.C.C and K.S wrote the manuscript, with assistance from J.R.H. and A.A.B.R. and input from all authors.
Corresponding authors
Ethics declarations
Competing interests
R.C.C., A.A.B.R. and K.S. are co-inventors on patent applications for NLRP3 inhibitors (WO2018215818, WO2017140778 and WO2016131098), which are licensed to Inflazome Ltd, a company headquartered in Dublin, Ireland. Inflazome is developing drugs that target the NLRP3 inflammasome to address unmet clinical needs in inflammatory disease.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Supplementary Information
Supplementary Table 1, Supplementary Figures 1–15
Supplementary Note
Synthetic Procedures
Rights and permissions
About this article
Cite this article
Coll, R.C., Hill, J.R., Day, C.J. et al. MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition. Nat Chem Biol 15, 556–559 (2019). https://doi.org/10.1038/s41589-019-0277-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41589-019-0277-7
- Springer Nature America, Inc.
This article is cited by
-
Targeting NLRP3 signaling reduces myocarditis-induced arrhythmogenesis and cardiac remodeling
Journal of Biomedical Science (2024)
-
The molecular mechanism of MiR-26a-5p regulates autophagy and activates NLRP3 inflammasome to mediate cardiomyocyte hypertrophy
BMC Cardiovascular Disorders (2024)
-
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets
Nature Reviews Drug Discovery (2024)
-
The role of inflammasomes in human diseases and their potential as therapeutic targets
Signal Transduction and Targeted Therapy (2024)
-
Britannin as a novel NLRP3 inhibitor, suppresses inflammasome activation in macrophages and alleviates NLRP3-related diseases in mice
Acta Pharmacologica Sinica (2024)